Trial · NCT01986881
Participant flow21
How many started, completed or left each group, period by period.
1 to 20 of 21
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Ertugliflozin 5 mg (Overall Cardiovascular Study) | 2,752 | |
| Overall Study | STARTED | Ertugliflozin 15 mg (Overall Cardiovascular Study) | 2,747 | |
| Overall Study | STARTED | Placebo (Overall Cardiovascular Study) | 2,747 | |
| Overall Study | Treated | Ertugliflozin 5 mg (Overall Cardiovascular Study) | 2,746 | |
| Overall Study | Treated | Ertugliflozin 15 mg (Overall Cardiovascular Study) | 2,747 | |
| Overall Study | Treated | Placebo (Overall Cardiovascular Study) | 2,745 | |
| Overall Study | Participants Enrolled in the Insulin +/- Metformin Glycemic Sub-Study | Ertugliflozin 5 mg (Overall Cardiovascular Study) | 348 | |
| Overall Study | Participants Enrolled in the Insulin +/- Metformin Glycemic Sub-Study | Ertugliflozin 15 mg (Overall Cardiovascular Study) | 370 | |
| Overall Study | Participants Enrolled in the Insulin +/- Metformin Glycemic Sub-Study | Placebo (Overall Cardiovascular Study) | 347 | |
| Overall Study | Participants Enrolled in the Sulfonylurea Monotherapy Glycemic Sub-Study | Ertugliflozin 5 mg (Overall Cardiovascular Study) | 55 | |
| Overall Study | Participants Enrolled in the Sulfonylurea Monotherapy Glycemic Sub-Study | Ertugliflozin 15 mg (Overall Cardiovascular Study) | 54 | |
| Overall Study | Participants Enrolled in the Sulfonylurea Monotherapy Glycemic Sub-Study | Placebo (Overall Cardiovascular Study) | 48 | |
| Overall Study | Participants Enrolled in the Metformin With Sulfonylurea Glycemic Sub-Study | Ertugliflozin 5 mg (Overall Cardiovascular Study) | 100 | |
| Overall Study | Participants Enrolled in the Metformin With Sulfonylurea Glycemic Sub-Study | Ertugliflozin 15 mg (Overall Cardiovascular Study) | 113 | |
| Overall Study | Participants Enrolled in the Metformin With Sulfonylurea Glycemic Sub-Study | Placebo (Overall Cardiovascular Study) | 117 | |
| Overall Study | COMPLETED | Ertugliflozin 5 mg (Overall Cardiovascular Study) | 2,422 | |
| Overall Study | COMPLETED | Ertugliflozin 15 mg (Overall Cardiovascular Study) | 2,401 | |
| Overall Study | COMPLETED | Placebo (Overall Cardiovascular Study) | 2,389 | |
| Overall Study | NOT COMPLETED | Ertugliflozin 5 mg (Overall Cardiovascular Study) | 330 | |
| Overall Study | NOT COMPLETED | Ertugliflozin 15 mg (Overall Cardiovascular Study) | 346 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01986881/flow